The UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR): Eli Lilly Engagement with A-STAR

Study identification

• EU PAS number:
  EUPAS108949
• Study ID:
  199014
• Official title and acronym:
  The UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR): Eli Lilly Engagement with A-STAR
• DARWIN EU® study:
  No
• Study countries:
  Ireland

  United Kingdom (Northern Ireland)
• Study description:
  The A-STAR Study is linked to the European Treatment of Severe Atopic Eczema Taskforce (TREAT Europe). This EU PAS Entry is meant to reflect Eli Lilly's engagement with A-STAR to collect data for baricitinib to treat patients with atopic dermatitis. A-STAR is a multi-centre, prospective, observational clinical registry of patients with atopic eczema on systemic immuno-modulatory therapies. Children and adults with atopic eczema starting on, or switching to another, systemic immunomodulatory therapy are eligible via participating dermatology centres. The primary objective is to estimate the short- and long-term effectiveness of systemic immunomodulatory therapies. The study aims to monitor patients for at least 12 months and, if possible, for many years thereafter.
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Actual:07/12/2020

Study start date

Actual:16/03/2021

Date of final study report

Planned:31/12/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable